All Articles
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown
On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.
HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity
ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.
A Journey of a Thousand Miles Begins with a Single Step Navigating the Path to a Leadership Position
In this personal reflection from the latest issue of HOPA News, Mary Walters, PharmD, BCOP, and Peter Stuessy, PharmD, BCOP, compare and contrast their journeys into leadership roles - and what advice they would give others on their own leadership paths.
Record-Breaking Hill Day Participation Brings HOPA Advocacy, Education to D.C.
HOPA members and staff were hard at work in the nation's capital for HOPA Hill Day on Tuesday, Sept. 30, discussing the hem/onc pharmacy profession and the important issues facing optimized cancer care across the nation.
Leading Cancer Organizations Launch New Patient Education Sheets Website
The new Patient Education Sheets (PES) website is here! Created by NCODA, HOPA, ONS, and ACCC, this updated platform replaces the OCE and IVE websites, offering over 300 trusted, patient-friendly resources to support cancer care.
Late-Breaking HOPA News: Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer
Ming-Hei Tai, PharmD, BCOP, and Alexis Chapman, PharmD, BCOP, discuss the IMforte trial concerning lurbinectedin and atezolizumab in the treatment of extensive-stage small cell lung cancer.
